From costly to cost-effective: rethinking commissioning of anti-obesity medications
From costly to cost-effective: rethinking commissioning of anti-obesity medications
13 PagesObesity affects 14M UK adults today and is forecast to reach 20M by 2030, costing the NHS £11.4B annually and the wider economy £98B. While NICE has recommended drugs like semaglutide and tirzepatide, ICBs face concerns over affordability, with potential annual costs of £3–5.5B, and limited MDT capacity in primary and secondary care. To address this, Reset Health and IQVIA propose a Community Obesity Management Service combining data-driven patient targeting, digital wraparound support via Roczen, and real-world evidence tracking. This model widens access, reduces health inequalities, alleviates GP burden, and makes obesity care cost-effective.
